BiomX Inc. Q2 Earnings Call: Clinical Advancements Amid Financial Caution

BiomX Inc. reported Q2 earnings, highlighting clinical advancements and financial caution. The company initiated its BX004 Phase IIb trial, published in Nature Communications, and reported positive Phase II results for BX211. BiomX received funding support from the U.S. Defense Health Agency but reported a decrease in its cash balance and a net loss of $6 million. The company expects its cash balance to sustain operations into Q1 2026.